Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.Vaccine · 2018
   Article
2. A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population.Scientific reports · 2016
   Article
3. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.EBioMedicine · 2015
   Article
4. Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.AIDS patient care and STDs · 2015
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as